<DOC>
	<DOCNO>NCT02101580</DOCNO>
	<brief_summary>Assessment safety tolerability ADI-PEG 20 plus nab-Paclitaxel Gemcitabine subject Advanced Pancreatic Carcinoma .</brief_summary>
	<brief_title>Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel Gemcitabine Subjects With Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis pancreatic carcinoma ( dose escalation MTD expansion component ) . 2 . Subjects doseescalation component 1 prior line systemic therapy . Subjects pancreatic carcinoma enrol MTD expansion cohort must untreated , measurable metastatic disease . Subjects MTD cohort may receive prior adjuvant gemcitabine fluoropyrimidine base therapy adjuvant setting provide 6 month elapse follow completion adjuvant therapy . 3 . Unresectable disease subject refuse surgery . 4 . Progressive disease treat chemotherapy , radiotherapy , surgery immunotherapy . If prior radiation give , measurable disease outside radiation port . 5 . Measurable disease assess RECIST 1.1 criterion ( Appendix A ) . 6 . Age ≥ 18 year . 7 . ECOG performance status 0 1 . 8 . No prior systemic therapy , immunotherapy , investigational agent , radiation therapy within last 4 week . Radiation therapy symptomatic relief allow within last 2 week . 1 . Serious infection require treatment systemically administer antibiotic time study entrance , infection require systemic antibiotic therapy within 7 day prior first dose study treatment . 2 . Serious underlie lung function abnormality due risk fatal pneumonitis cause combination Abraxane gemcitabine 3 . Grade 2 high neuropathy ( CTCAE V4.0 ) 4 . Prior treatment nabpaclitaxel . 5 . Pregnancy lactation . 6 . Expected noncompliance . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV ) , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement . 8 . Subjects anticancer treatment prior enter study recover baseline ( except alopecia ) ≤ Grade 1 AEs , deem irreversible effect prior cancer therapy . AEs &gt; Grade 1 consider safety risk Sponsor investigator may allow upon agreement , include residual neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>argininosuccinate synthetase</keyword>
	<keyword>arginine</keyword>
	<keyword>arginine deiminase</keyword>
</DOC>